E. A. Perez, Rhabdomyosarcoma in children: a SEER population based study, J. Surg. Res, vol.170, pp.243-251, 2011.

D. M. Parham and F. G. Barr, Classification of rhabdomyosarcoma and its molecular basis, Adv. Anat. Pathol, vol.20, pp.387-397, 2013.

J. L. Meza, J. Anderson, A. S. Pappo, and W. H. Meyer, Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.24, pp.3844-3851, 2006.

O. Oberlin, Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.26, pp.2384-2389, 2008.

R. J. Davis, C. M. Cruz, M. A. Lovell, J. A. Biegel, and F. G. Barr, Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma, Cancer Res, vol.54, pp.2869-2872, 1994.

N. Galili, Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma, Nat. Genet, vol.5, pp.230-235, 1993.

D. Williamson, Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.28, pp.2151-2158, 2010.

E. R. Rudzinski, NOS-1, and HMGA2 are surrogate markers of fusion status in rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children's oncology group, Am. J. Surg. Pathol, vol.2, pp.654-659, 2014.

C. J. Drummond, Hedgehog Pathway Drives Fusion-Negative Rhabdomyosarcoma Initiated From Non-myogenic Endothelial Progenitors, Cancer Cell, vol.33, 2018.

M. E. Hatley, A mouse model of rhabdomyosarcoma originating from the adipocyte lineage, Cancer Cell, vol.22, pp.536-546, 2012.

J. E. Sewell, S. K. Davis, and P. S. Hargis, Isolation, characterization, and expression of fatty acid binding protein in the liver of Gallus domesticus, Comp. Biochem. Physiol. B, vol.92, pp.509-516, 1989.

K. J. Thompson, Altered fatty acid-binding protein 4 (FABP4) expression and function in human and animal models of hepatocellular carcinoma, Liver Int. Off. J. Int. Assoc. Study Liver, vol.38, pp.1074-1083, 2018.

T. Iso, Capillary endothelial fatty acid binding proteins 4 and 5 play a critical role in fatty acid uptake in heart and skeletal muscle, Arterioscler. Thromb. Vasc. Biol, vol.33, pp.2549-2557, 2013.

T. Fuseya, Ectopic Fatty Acid-Binding Protein 4 Expression in the Vascular Endothelium is Involved in Neointima Formation After Vascular Injury, J. Am. Heart Assoc, vol.6, 2017.

H. Elmasri, Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells, FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol, vol.23, pp.3865-3873, 2009.

K. B. Jones, What's in a Name? Cell Fate Reprogramming in Sarcomagenesis, Cancer Cell, vol.33, pp.5-7, 2018.

K. K. Slemmons, A Novel Notch-YAP Circuit Drives Stemness and Tumorigenesis in Embryonal Rhabdomyosarcoma, Mol. Cancer Res. MCR, vol.15, pp.1777-1791, 2017.

L. E. Crose, Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression, J. Clin. Invest, vol.124, pp.285-296, 2014.

A. A. Ahmed, Potential Value of YAP Staining in Rhabdomyosarcoma, J. Histochem. Cytochem. Off. J. Histochem. Soc, vol.66, pp.577-584, 2018.

S. S. Raghavan, K. L. Mooney, A. L. Folpe, and G. W. Charville, OLIG2 is a marker of the fusion protein-driven neurodevelopmental transcriptional signature in alveolar rhabdomyosarcoma, Hum. Pathol, vol.91, pp.77-85, 2019.

J. A. Hemminger, The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas, Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc, vol.26, pp.282-288, 2013.

J. R. Toro, Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, Int. J. Cancer, vol.119, pp.2922-2930, 1978.

C. R. Antonescu, Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.7, pp.3977-3987, 2001.

J. A. Hemminger and O. H. Iwenofu, NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms, Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc, vol.26, pp.1204-1210, 2013.

A. A. Jungbluth, Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues, Int. J. Cancer, vol.92, pp.856-860, 2001.

T. Nicholaou, Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1, Immunol. Cell Biol, vol.84, pp.303-317, 2006.

G. Cronwright, Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression, Cancer Res, vol.65, pp.2207-2215, 2005.

A. J. Zendman, D. J. Ruiter, and G. N. Van-muijen, Cancer/testis-associated genes: identification, expression profile, and putative function, J. Cell. Physiol, vol.194, pp.272-288, 2003.

H. Xu, NY-ESO-1 expression in hepatocellular carcinoma: A potential new marker for early recurrence after surgery, Oncol. Lett, vol.3, pp.39-44, 2012.

A. O. Gure, Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.11, pp.8055-8062, 2005.

F. O. Ademuyiwa, NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer, PloS One, vol.7, p.38783, 2012.

A. A. Jungbluth, Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7, Int. J. Cancer, vol.94, pp.252-256, 2001.

M. Ayyoub, The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma, Cancer Immun, vol.4, p.7, 2004.

S. M. Pollack, NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma, Cancer, vol.118, pp.4564-4570, 2012.

J. A. Hemminger and O. H. Iwenofu, NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms, Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc, vol.26, pp.1204-1210, 2013.

M. J. Scanlan, A. O. Gure, A. A. Jungbluth, L. J. Old, and Y. Chen, Cancer/testis antigens: an expanding family of targets for cancer immunotherapy, Immunol. Rev, vol.188, pp.22-32, 2002.

A. Woloszynska-read, P. Mhawech-fauceglia, J. Yu, K. Odunsi, and A. R. Karpf, Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoterspecific and global DNA methylation status in ovarian cancer, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.14, pp.3283-3290, 2008.

M. Laé, Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas, J. Pathol, vol.212, pp.143-151, 2007.

E. Davicioni, Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group, Am. J. Pathol, vol.174, pp.550-564, 2009.

K. Nishijo, Credentialing a Preclinical Mouse Model of Alveolar Rhabdomyosarcoma, Cancer Res, vol.69, pp.2902-2911, 2009.

L. Tombolan, NELL1, whose high expression correlates with negative outcomes, has different methylation patterns in alveolar and embryonal rhabdomyosarcoma, Oncotarget, vol.8, pp.33086-33099, 2017.

M. Wachtel, Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.24, pp.816-822, 2006.

M. Furuhashi, Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice, J. Clin. Invest, vol.118, pp.2640-2650, 2008.

L. Makowski, Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis, Nat. Med, vol.7, pp.699-705, 2001.

G. S. Hotamisligil, Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein, Science, vol.274, pp.1377-1379, 1996.

A. J. Simpson, O. L. Caballero, A. Jungbluth, Y. Chen, and L. J. Old, Cancer/testis antigens, gametogenesis and cancer, Nat. Rev. Cancer, vol.5, pp.615-625, 2005.

O. L. Caballero and Y. Chen, Cancer/testis (CT) antigens: potential targets for immunotherapy, Cancer Sci, vol.100, 2009.

R. Thomas, NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives, Front. Immunol, vol.9, p.947, 2018.

N. P. Agaram, M. P. Laquaglia, R. Alaggio, L. Zhang, Y. Fujisawa et al., MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification Mod Pathol, 2018.

N. P. Agaram, L. Zhang, Y. S. Sung, M. S. Cavalcanti, D. Torrence et al., Expanding the Spectrum of Intraosseous Rhabdomyosarcoma: Correlation Between 2 Distinct Gene Fusions and Phenotype, Am J Surg Pathol, vol.43, pp.695-702, 2019.

R. Alaggio, L. Zhang, Y. S. Sung, S. C. Huang, C. L. Chen et al., A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma: Identification of Novel and Recurrent VGLL2-related Fusions in Infantile Cases, Am J Surg Pathol, vol.40, pp.224-235, 2016.

F. G. Barr, S. J. Qualman, M. H. Macris, N. Melnyk, E. R. Lawlor et al., Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions, Cancer Res, vol.62, pp.4704-4710, 2002.

J. L. Bennicelli, R. H. Edwards, and F. G. Barr, Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma, Proc Natl Acad Sci U S A, vol.93, pp.5455-5459, 1996.

J. A. Bridge, J. Liu, S. J. Qualman, R. Suijkerbuijk, G. Wenger et al., Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes, Genes Chromosomes Cancer, vol.33, pp.310-321, 2002.

J. A. Bridge, J. Sumegi, M. Druta, M. M. Bui, E. Henderson-jackson et al., Clinical, pathological, and genomic features of EWSR1-PATZ1 fusion sarcoma Mod Pathol, 2019.

C. M. Fletcher, C. Bj, and P. Hogendoorn, Mertens F (ed) WHO classification of Tumours of soft tissue and bone, p.191, 2013.

S. D. Carvalho, D. Pissaloux, A. Crombe, J. M. Coindre, L. Loarer et al., Pleomorphic Sarcomas: The State of the Art, Surg Pathol Clin, vol.12, pp.63-105, 2019.

L. Chen, J. F. Shern, J. S. Wei, M. E. Yohe, Y. K. Song et al., Clonality and evolutionary history of rhabdomyosarcoma, PLoS Genet, vol.11, 2015.

A. Chougule, M. S. Taylor, V. Nardi, I. Chebib, G. M. Cote et al., Spindle and Round Cell Sarcoma With EWSR1-PATZ1 Gene Fusion: A Sarcoma With Polyphenotypic Differentiation, Am J Surg Pathol, vol.43, pp.220-228, 2019.

D. Li-fraumeni, C. Fletcher, . Bj, and P. Hogendoorn, Mertens F (ed) WHO classification of Tumours of soft tissue and bone, pp.379-381, 2013.

T. M. Dantonello, I. Leuschner, C. Vokuhl, S. Gfroerer, A. Schuck et al., Malignant ectomesenchymoma in children and adolescents: report from the Cooperative Weichteilsarkom Studiengruppe, vol.60, pp.224-229, 2013.

N. K. Dashti, R. N. Wehrs, B. C. Thomas, A. Nair, J. Davila et al., Spindle cell rhabdomyosarcoma of bone with FUS-TFCP2 fusion: confirmation of a very recently described rhabdomyosarcoma subtype, Histopathology, vol.73, pp.514-520, 2018.

L. P. Dehner, J. A. Jarzembowski, and D. A. Hill, Embryonal rhabdomyosarcoma of the uterine cervix: a report of 14 cases and a discussion of its unusual clinicopathological associations, Mod Pathol, vol.25, pp.602-614, 2012.

A. L. Folpe, Mesenchymal chondrosarcomas showing immunohistochemical evidence of rhabdomyoblastic differentiation: a potential diagnostic pitfall, 2018.

A. L. Folpe, Sclerosing rhabdomyosarcoma in adults: report of four cases of a hyalinizing, matrix-rich variant of rhabdomyosarcoma that may be confused with ost, 2018.

A. L. Folpe, R. P. Graham, A. Martinez, D. Schembri-wismayer, J. Boland et al., Mesenchymal chondrosarcomas showing immunohistochemical evidence of rhabdomyoblastic differentiation: a potential diagnostic pitfall, Hum Pathol, vol.77, pp.28-34, 2018.

M. A. Furlong, T. Mentzel, and J. C. Fanburg-smith, Pleomorphic rhabdomyosarcoma in adults: a clinicopathologic study of 38 cases with emphasis on morphologic variants and recent skeletal muscle-specific markers, Mod Pathol, vol.14, pp.595-603, 2001.

K. W. Gripp, Tumor predisposition in Costello syndrome, Am J Med Genet C Semin Med Genet, vol.137, pp.72-77, 2005.

A. Gronchi, P. Collini, R. Miceli, B. Valeri, S. L. Renne et al., Myogenic differentiation and histologic grading are major prognostic determinants in retroperitoneal liposarcoma, Am J Surg Pathol, vol.39, pp.383-393, 2015.

S. Hettmer, N. M. Archer, G. R. Somers, A. Novokmet, A. J. Wagers et al., Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers, Cancer, vol.120, pp.1068-1075, 2014.

S. Hettmer, L. A. Teot, H. Kozakewich, A. M. Werger, K. J. Davies et al., Myogenic tumors in nevoid Basal cell carcinoma syndrome, J Pediatr Hematol Oncol, vol.37, pp.147-149, 2015.

S. C. Huang, R. Alaggio, Y. S. Sung, C. L. Chen, L. Zhang et al., Frequent HRAS Mutations in Malignant Ectomesenchymoma: Overlapping Genetic Abnormalities With Embryonal Rhabdomyosarcoma, Am J Surg Pathol, 2016.

V. Y. Jo, A. Mariño-enríquez, and C. D. Fletcher, Epithelioid rhabdomyosarcoma: clinicopathologic analysis of 16 cases of a morphologically distinct variant of rhabdomyosarcoma, Am J Surg Pathol, vol.35, pp.1523-1530, 2011.

R. Kodet, W. A. Newton, A. B. Hamoudi, and L. Asmar, Rhabdomyosarcomas with intermediate-filament inclusions and features of rhabdoid tumors. Light microscopic and immunohistochemical study, Am J Surg Pathol, vol.15, pp.257-267, 1991.

R. Kodet, W. A. Newton, A. B. Hamoudi, L. Asmar, D. L. Jacobs et al., Childhood rhabdomyosarcoma with anaplastic (pleomorphic) features. A report of the Intergroup Rhabdomyosarcoma Study, Am J Surg Pathol, vol.17, pp.443-453, 1993.

C. Koelsche, M. Mynarek, D. Schrimpf, L. Bertero, J. Serrano et al., Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations, Acta Neuropathol, vol.136, pp.327-337, 2018.

S. Kohsaka, N. Shukla, N. Ameur, T. Ito, C. K. Ng et al., A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations, Nat Genet, vol.46, pp.595-600, 2014.

E. Legius, C. Bh-;-fletcher, . Bj, and P. Hogendoorn, Mertens F (ed) WHO classification of Tumours of soft tissue and bone, pp.386-387, 2013.

I. Leuschner, W. A. Newton, D. Schmidt, N. Sachs, L. Asmar et al., Spindle cell variants of embryonal rhabdomyosarcoma in the paratesticular region. A report of the Intergroup Rhabdomyosarcoma Study, Am J Surg Pathol, vol.17, pp.221-230, 1993.

J. Liu, M. A. Guzman, D. Pezanowski, D. Patel, J. Hauptman et al., FOXO1-FGFR1 fusion and amplification in a solid variant of alveolar rhabdomyosarcoma, Mod Pathol, vol.24, pp.1327-1335, 2011.

T. Maeda, D. L. Chapman, and A. F. Stewart, Mammalian vestigial-like 2, a cofactor of TEF-1 and MEF2 transcription factors that promotes skeletal muscle differentiation, The Journal of biological chemistry, vol.277, pp.48889-48898, 2002.

S. Martinelli, H. P. Mcdowell, S. D. Vigne, G. Kokai, S. Uccini et al., RAS signaling dysregulation in human embryonal, Rhabdomyosarcoma Genes Chromosomes Cancer, vol.48, pp.975-982, 2009.

A. P. Martinez, K. J. Fritchie, S. W. Weiss, A. Agaimy, F. Haller et al., Histiocyte-rich rhabdomyoblastic tumor: rhabdomyosarcoma, rhabdomyoma, or rhabdomyoblastic tumor of uncertain malignant potential? A histologically distinctive rhabdomyoblastic tumor in search of a place in the classification of skeletal muscle neoplasms, Mod Pathol, vol.32, pp.446-457, 2019.

T. Mentzel and D. Katenkamp, Sclerosing, pseudovascular rhabdomyosarcoma in adults. Clinicopathological and immunohistochemical analysis of three cases, Virchows Arch, vol.436, pp.305-311, 2000.

T. Mentzel and C. Kuhnen, Spindle cell rhabdomyosarcoma in adults: clinicopathological and immunohistochemical analysis of seven new cases, Virchows Arch, vol.449, pp.554-560, 2006.

J. M. Mosquera, A. Sboner, L. Zhang, N. Kitabayashi, C. L. Chen et al., Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma, Genes Chromosomes Cancer, vol.52, pp.134-135, 2013.

O. Oberlin, A. Rey, E. Lyden, G. Bisogno, M. C. Stevens et al., Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups, J Clin Oncol, vol.26, pp.2384-2389, 2008.

D. M. Parham, M. E. Bfg, and A. F. Nascimento, ed) WHO classification of Tumours of soft tissue and bone, pp.127-135, 2013.

D. M. Parham, F. Barr, C. Fletcher, . Bj, and P. Hogendoorn, Mertens F (ed) WHO classification of Tumours of soft tissue and bone, pp.124-126, 2013.

V. Paulson, G. Chandler, D. Rakheja, R. L. Galindo, K. Wilson et al., The myocardin family of transcriptional coactivators: versatile regulators of cell growth, migration, and myogenesis, Genes Chromosomes Cancer, vol.50, pp.1545-1556, 2006.

S. Qualman, J. Lynch, J. Bridge, D. Parham, L. Teot et al., Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children's, Oncology Group Cancer, vol.113, pp.3242-3247, 2008.

B. Rekhi, C. Gupta, G. Chinnaswamy, S. Qureshi, T. Vora et al., Clinicopathologic features of 300 rhabdomyosarcomas with emphasis upon differential expression of skeletal muscle specific markers in the various subtypes: A single institutional experience, Ann Diagn Pathol, vol.36, pp.50-60, 2018.

B. Rekhi, P. Upadhyay, M. P. Ramteke, and A. Dutt, MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes, Mod Pathol, vol.29, pp.1532-1540, 2016.

B. P. Rubin, K. Nishijo, H. I. Chen, X. Yi, D. P. Schuetze et al., Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma, Cancer Cell, vol.19, pp.177-191, 2011.

P. Schoffski, A. Wozniak, M. G. Leahy, S. Aamdal, P. Rutkowski et al., The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE, Eur J Cancer, vol.94, pp.156-167, 2018.

M. Seki, R. Nishimura, K. Yoshida, T. Shimamura, Y. Shiraishi et al., Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma, Nat Commun, vol.6, p.7557, 2015.

J. F. Shern, L. Chen, J. Chmielecki, J. S. Wei, R. Patidar et al., Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors Cancer discovery, vol.4, pp.216-231, 2014.

N. Shukla, N. Ameur, I. Yilmaz, K. Nafa, C. Y. Lau et al., Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways, Clin Cancer Res, vol.18, pp.748-757, 2012.

N. Stock, F. Chibon, M. B. Binh, P. Terrier, J. J. Michels et al., Adult-type rhabdomyosarcoma: analysis of 57 cases with clinicopathologic description, identification of 3 morphologic patterns and prognosis, Am J Surg Pathol, vol.33, pp.1850-1859, 2009.

J. Sumegi, R. Streblow, R. W. Frayer, P. Dal-cin, A. Rosenberg et al., Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family, Genes Chromosomes Cancer, vol.49, pp.224-236, 2010.

K. Szuhai, D. De-jong, W. Y. Leung, C. D. Fletcher, and P. C. Hogendoorn, Transactivating mutation of the MYOD1 gene is a frequent event in adult spindle cell rhabdomyosarcoma, J Pathol, vol.232, pp.300-307, 2014.

J. W. Tsai, Y. C. Changchien, J. C. Lee, Y. C. Kao, W. S. Li et al., The expanding morphological and genetic spectrum of MYOD1-mutant spindle cell/sclerosing rhabdomyosarcomas: a clinicopathological and molecular comparison of mutated and non-mutated cases, Histopathology, vol.74, pp.933-943, 2019.

S. Watson, V. Perrin, D. Guillemot, S. Reynaud, J. M. Coindre et al., Transcriptomic definition of molecular subgroups of small round cell sarcomas, J Pathol, vol.245, pp.29-40, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02440510

D. Williamson, E. Missiaglia, A. De-reynies, G. Pierron, B. Thuille et al., Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma, J Clin Oncol, vol.28, pp.2151-2158, 2010.

D. D. Wong, C. Van-vliet, A. Gaman, T. Giardina, and B. Amanuel, Rhabdomyosarcoma with FUS re-arrangement: additional case in support of a novel subtype, Pathology, vol.51, pp.116-120, 2019.

A. Zin, R. Bertorelle, P. Dall'igna, C. Manzitti, C. Gambini et al., Epithelioid rhabdomyosarcoma: a clinicopathologic and molecular study, Am J Surg Pathol, vol.38, pp.273-278, 2014.

. Serment-d'hippocrate,

, Au moment d'être admise à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences

, Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire

, Admise dans l'intimité des personnes, je tairai les secrets qui me seront confiés. Reçue à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses

, que je sois déshonorée et méprisée si j'y manque

, Les rhabdomyosarcomes (RMS) sont des tumeurs malignes associées à une différenciation musculaire striée dont les 2 sous-types les plus fréquents sont le RMS alvéolaire (ARMS) et le RMS embryonnaire (ERMS). Les ARMS, de plus mauvais pronostic, présentent dans 85% une translocation conduisant à l'expression d'une protéine de fusion PAX3-FOXO1 ou PAX7-FOXO1. En pratique clinique, les équipes exigent souvent de connaitre le statut de FOXO1 pour

, Notre objectif était de mettre au point un marqueur immunohistochimique pour le diagnostic différentiel ERMS/ARMS afin de réduire les indications au screening moléculaire. A partir de données transcriptomique et de la littérature, nous avons identifié 3 marqueurs putatifs: AP2b, FABP4, et YAP1

, L'analyse des lames de Tissu Micro-Array (TMA) de sarcomes pour la mise au point du marquage de FABP4 a permis d'identifier fortuitement une forte expression de FABP4 dans les liposarcomes

, NY-ESO1. Nos résultats indiquent que FABP4 est très sensible dans les LPS myxoïdes/à cellules rondes, supérieur à NY-ESO1. Toutefois FABP4 est moins spécifique, car observé dans toutes les tumeurs adipeuses alors que l'expression de NY-ESO1 est restreinte aux LPS myxoides/cellules rondes et rarement observée dans les autres tumeurs myxoïdes. L' utilisation combinée de ces marqueurs pourrait donc être discutée pour le diagnostic des LPS myxoïdes/cellules rondes, permettant une épargne du screening moléculaire (jusqu'ici était systématique selon les recommandations de bonne pratique du réseau RRePS). NY-ESO1, myxoïdes/à cellules rondes. L'expression de FABP4 a donc été secondairement étudiée dans ces tumeurs en comparant ses performances avec l'anticorps de référence